N-[4-({4-methyl-3,5,9-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(14),2(6),4,10,12-pentaen-9-yl}carbonyl)phenyl]-2-phenylbenzamide hydrochloride
| Title | Journal |
|---|---|
| Hyponatremia, heart failure, and the role of tolvaptan. | Postgraduate medicine 20120301 |
| The roles of V1a vasopressin receptors in blood pressure homeostasis: a review of studies on V1a receptor knockout mice. | Clinical and experimental nephrology 20120201 |
| Hyponatremia and the use of vasopressin receptor antagonists in critically ill patients. | Journal of intensive care medicine 20120101 |
| Novel treatment targets for cerebral edema. | Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20120101 |
| [Hyponatremic syndrome]. | La Clinica terapeutica 20120101 |
| [Hyponatremic hypervolemia in heart failure--the hot spot for vasopressin receptor antagonists?]. | Wiadomosci lekarskie (Warsaw, Poland : 1960) 20120101 |
| Conivaptan therapy in an infant with severe hyponatremia and congestive heart failure. | Texas Heart Institute journal 20120101 |
| Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure. | Journal of cardiac failure 20111201 |
| Controlling the flood gates: vaptans, furosemide and the quest for a renal protective diuresis. | Journal of cardiac failure 20111201 |
| Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists? | Current heart failure reports 20110901 |
| Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet. | Kidney international 20110901 |
| Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion. | Neurosurgery 20110801 |
| The therapeutic use of vaptans for the treatment of dilutional hyponatremia. | Journal of pharmacy practice 20110801 |
| Open-label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury. | Neurocritical care 20110601 |
| Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110501 |
| Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). | European journal of clinical pharmacology 20110401 |
| Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110401 |
| Hyponatremia: vasopressin antagonists in hyponatremia: more data needed. | Nature reviews. Nephrology 20110301 |
| A bolus of conivaptan lowers intracranial pressure in a patient with hyponatremia after traumatic brain injury. | Neurocritical care 20110201 |
| Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model. | American journal of therapeutics 20110101 |
| The syndrome of inappropriate antidiuresis: pathophysiology, clinical management and new therapeutic options. | Nephron. Clinical practice 20110101 |
| Hyponatremia in acute decompensated heart failure: mechanisms, prognosis, and treatment options. | Clinical cardiology 20101101 |
| Extreme correction of hyponatremia in a patient treated with intravenous conivaptan. | Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20101001 |
| Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents. | Drug discovery today 20101001 |
| Use of Conivaptan (Vaprisol) for hyponatremic neuro-ICU patients. | Neurocritical care 20100801 |
| Synthesis and evaluation of azabicyclo[3.2.1]octane derivatives as potent mixed vasopressin antagonists. | Bioorganic & medicinal chemistry letters 20100615 |
| Use of conivaptan for the treatment of symptomatic hyponatremia in a patient with acute decompensated heart failure. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100615 |
| Sodium, potassium and glucose management in organ transplantation. | Current opinion in organ transplantation 20100601 |
| Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100501 |
| The vaptans: just landed. But how was the trip? | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20100501 |
| The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. | Journal of cardiac failure 20100501 |
| [Hyponatremia in heart failure: physiopathology and pharmacological approach]. | Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20100501 |
| [Vasopressin receptor antagonists: the vaptans]. | Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20100501 |
| Vasopressin antagonists: Pharmacotherapy for the treatment of heart failure. | The Annals of pharmacotherapy 20100401 |
| Vasopressin receptor antagonist use in a neurologic rehabilitation center. | The journal of spinal cord medicine 20100201 |
| Hyponatremia: evaluation and management. | Hospital practice (1995) 20100201 |
| Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure. | Heart failure reviews 20100101 |
| Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan. | Cardiology in review 20100101 |
| Tolvaptan (Samsca) for hyponatremia. | The Medical letter on drugs and therapeutics 20091130 |
| [Vasopressin receptor antagonists and heart failure]. | Therapeutische Umschau. Revue therapeutique 20091101 |
| Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20091001 |
| Conivaptan: promise of treatment in heart failure. | Expert opinion on pharmacotherapy 20090901 |
| Successful treatment of ifosfamide-induced hyponatremia with AVP receptor antagonist without interruption of hydration for prevention of hemorrhagic cystitis. | Annals of oncology : official journal of the European Society for Medical Oncology 20090701 |
| Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. | Clinical therapeutics 20090701 |
| Pharmacology of vasopressin antagonists. | Heart failure reviews 20090601 |
| AVP receptor antagonists in patients with CHF. | Heart failure reviews 20090601 |
| Hyponatremia: case vignettes. | Seminars in nephrology 20090501 |
| Conivaptan for hyponatremia in the neurocritical care unit. | Neurocritical care 20090101 |
| Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. | The American journal of the medical sciences 20090101 |
| Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. | Neurocritical care 20090101 |
| New topics in vasopressin receptors and approach to novel drugs: research and development of conivaptan hydrochloride (YM087), a drug for the treatment of hyponatremia. | Journal of pharmacological sciences 20090101 |
| Role of vasopressin and vasopressin receptor antagonists in type I cardiorenal syndrome. | Blood purification 20090101 |
| Hyponatremia in heart failure. | Journal of intensive care medicine 20090101 |
| Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. | Journal of cardiac failure 20081001 |
| Vasopressin antagonists for the treatment of acute decompensated heart failure: when, for whom, for how long, and on what standard therapy? | Journal of cardiac failure 20081001 |
| Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH. | Pediatric nephrology (Berlin, Germany) 20080801 |
| [Etiology, diagnostics and therapy of hyponatremias]. | Orvosi hetilap 20080720 |
| Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. | Clinical endocrinology 20080701 |
| Conivaptan: potential therapeutic implications in heart failure. | Recent patents on cardiovascular drug discovery 20080601 |
| Vasopressin and vasopressin antagonists in heart failure and hyponatremia. | Current heart failure reports 20080601 |
| Non-peptide arginine-vasopressin antagonists: the vaptans. | Lancet (London, England) 20080510 |
| Vasopressin-receptor antagonists in heart failure. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080501 |
| The management of ascites and hyponatremia in cirrhosis. | Seminars in liver disease 20080201 |
| Hyponatremia in psychiatric patients: update on evaluation and management. | Harvard review of psychiatry 20080101 |
| Observations regarding the use of the aquaretic agent conivaptan for treatment of hyponatremia. | International urology and nephrology 20080101 |
| Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. | Progress in brain research 20080101 |
| Intravenous conivaptan. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20080101 |
| Hyponatremia and vasopressin antagonism in congestive heart failure. | Clinical cardiology 20071101 |
| Current issues for nurse practitioners: Hyponatremia. | Journal of the American Academy of Nurse Practitioners 20071101 |
| Hyponatremia: clinical diagnosis and management. | The American journal of medicine 20070801 |
| [Vasopressin antagonists in treatment of hyponatremia]. | Polskie Archiwum Medycyny Wewnetrznej 20070801 |
| Conivaptan: new treatment for hyponatremia. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070701 |
| Clinical practice. The syndrome of inappropriate antidiuresis. | The New England journal of medicine 20070517 |
| New drugs 07, part I. | Nursing 20070201 |
| Management of hyponatremia and clinical use of vasopressin antagonists. | The American journal of the medical sciences 20070201 |
| Recognition and treatment of hyponatremia in acutely ill hospitalized patients. | Clinical therapeutics 20070201 |
| [Arginine vasopressin antagonism--new treatment option in chronic heart failure]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20070118 |
| A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). | Biological & pharmaceutical bulletin 20070101 |
| Therapeutic potential of vasopressin receptor antagonists. | Drugs 20070101 |
| Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in healthy volunteers. | Advances in therapy 20070101 |
| Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. | American journal of nephrology 20070101 |
| Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. | Cardiovascular drug reviews 20070101 |
| Vasopressin antagonists--progress and promise. | The New England journal of medicine 20061116 |
| Excipient hydrolysis and ester formation increase pH in a parenteral solution over aging. | International journal of pharmaceutics 20061115 |
| Molecule of the Month: Conivaptan hydrochloride. | Drug news & perspectives 20061101 |
| Hyponatremia in cirrhosis: clinical features and management. | Gastroenterologie clinique et biologique 20061001 |
| AVP receptor antagonists as aquaretics: review and assessment of clinical data. | Cleveland Clinic journal of medicine 20060901 |
| Vasopressin antagonists. | Cellular and molecular life sciences : CMLS 20060801 |
| Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. | The American journal of medicine 20060701 |
| Conivaptan (Vaprisol) for hyponatremia. | The Medical letter on drugs and therapeutics 20060619 |
| Cardiac function and heart failure. | Journal of the American College of Cardiology 20060606 |
| Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. | The Journal of clinical endocrinology and metabolism 20060601 |
| Vasopressin receptor antagonists. | Kidney international 20060601 |
| Conivaptan: a selective vasopressin antagonist. | Drugs of today (Barcelona, Spain : 1998) 20060601 |
| Vasopressin receptor antagonists in heart failure. | Recent patents on cardiovascular drug discovery 20060601 |
| Vasopressin excess and hyponatremia. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20060501 |
| Vaptans and the treatment of water-retaining disorders. | Seminars in nephrology 20060501 |
| Vasopressin receptor antagonists: pharmacological tools and potential therapeutic agents. | Autonomic & autacoid pharmacology 20060401 |
| Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. | Journal of the American Society of Nephrology : JASN 20060101 |
| Conivaptan: a selective vasopressin antagonist for the treatment of heart failure. | Expert review of cardiovascular therapy 20060101 |
| New drugs: rasagiline mesylate, conivaptan hydrochloride, and sunitinib malate. | Journal of the American Pharmacists Association : JAPhA 20060101 |
| New drugs for prevention, relief. How you might benefit if 3 medications win FDA approval. | Heart advisor 20051001 |
| Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors. | Pharmacological research 20050301 |
| Conivaptan Yamanouchi. | Current opinion in investigational drugs (London, England : 2000) 20050301 |
| Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. | European journal of pharmacology 20050110 |
| Vasopressin antagonists in heart failure. | Current heart failure reports 20041201 |
| Conivaptan: YM 087. | Drugs in R&D 20040101 |
| Vasopressin receptor antagonists in heart failure. | Current opinion in pharmacology 20031201 |
| 2,5-disubstituted 3,4-dihydro-2H-benzo[b][1,4]thiazepines as potent and selective V2 arginine vasopressin receptor antagonists. | Bioorganic & medicinal chemistry letters 20031117 |
| Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. | Clinical science (London, England : 1979) 20030701 |
| Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. | Journal of hepatology 20030601 |
| Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. | American heart journal 20030101 |
| Effect of conivaptan, a combined vasopressin V(1a) and V(2) receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs. | Pharmacological research 20021101 |
| Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction. | European journal of pharmacology 20020823 |
| [Treatment of heart failure: an update]. | Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology 20020701 |
| Vasopressin antagonists in CHF: ready for clinical trials? | Cardiovascular research 20020401 |
| Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition. | Cardiovascular research 20020401 |
| Body compartment volumes and composition after giving a vasopressin antagonist: changes are revealed by a tonicity balance. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020201 |
| Conivaptan (Yamanouchi). | Current opinion in investigational drugs (London, England : 2000) 20020101 |
| Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors. | Journal of computer-aided molecular design 20011201 |
| Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. | Circulation 20011113 |
| Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. | The American journal of medicine 20010501 |
| Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells. | British journal of pharmacology 19981201 |
| Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist. | Naunyn-Schmiedeberg's archives of pharmacology 19980101 |